Knight Therapeutics and Sumitomo Pharma enter into Exclusive Licensing Agreements to commercialize Sumitomo’s Canadian Portfolio

MONTREAL and MARLBOROUGH, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, and Sumitomo Pharma America Inc. (“SMPA”) announced today that Knight and SMPA’s affiliates have entered into exclusive license and supply agreements to commercialize MYFEMBREE^® (relugolix/estradiol/norethindrone acetate), ORGOVYX^® (relugolix) and vibegron in Canada, as well as an asset purchase agreement under which Knight will acquire certain mature products (the “Mature Products”, together with MYFEMBREE^®, ORGOVYX^® and vibegron, the “Products”). For the year ended March 2025, the Products generated C$11.2 million in revenue.

Read more at globenewswire.com